FINANCIAL INFORMATION CONCERNING THE GROUP’S ASSETS AND LIABILITIES, FINANCIAL POSITIONAND PROFITS AND LOSSES 20 16.3 Free shares (AGA) In July 2017 and in December 2017, the Company’s Board of Vesting schedule Directors granted an aggregate of 666,000 additional AGA 2016 In July 2016, the Company’s Board of Directors granted an as follows: aggregate of 766,000 free shares (AGA 2016) as follows: • 622,500 AGA 2016, which may be ful ly acquired by key • 710,000 AGA 2016 (of which 128,000 were canceled in managers, including Mr. Bernard Gilly, subject to (i) a one year July 2017) may be fully acquired by key managers, including acquisition period from the date of grant and (ii) achievement Mr. Bernard Gilly, the Chief Executive Officer of the Company, of the performance criteria described below no later than subject to the achievement of the fol lowing performance July 2019: criteria no later than July 2018: – 311,250 of these free shares will be acquired upon receipt of – 291,000 of these free shares were acquired at the the definitive results of the GS010 REVERSE clinical trial; and completion of enrollment in RESCUE and REVERSE clinical – the remaining 311,250 free shares wil l be acquired upon trials; and completion of the enrol lment of 50% of the patients of a – the remaining 291,000 free shares will be acquired at the Phase I/I I clinical trialof GS30 in RP.0 enrollment of the first patient in a Phase I/I I clinical trial of• 43,500 AGA 2016 will be fully acquired on July 2018 (one year GS030 in RP. after their grant date). • 56,000 AGA 2016 were fully acquired in July 2017 (one year The AGA 2016 will be issued at their nominal value and will be after their grant date). subject to a lock-up period of one year after their acquisition date. Details and main characteristics of the AGA granted to date AGA 2016 AGA 2016 AGA 2016 Date of grant July 26, 2016 July 27, 2017 December 19, 2017 Number of Share Awards initially granted 766,000 593,500 72,500 Vesting period (in Years) 1 1 1 Grant date Fair-value €8.08 €5.12 €5.55 Performance conditions (1) Yes Yes Yes (1) Performance conditions concern only grants to key managers, other employees are only subject to a service condition. Changes in the balances of AGA AGA 2016 Balance outstanding at January 1, 2017 763,000 Granted during the period 666,000 Vested during the period (347,000) Forfeited during the period (125,000) Balance outstanding at December 31, 2017 957,000 16.4 Stock options (SO) • the remaining 75% becoming exercisable up to 1/36 per month Vesting schedule from the date of grant; and The SO 2017 granted on December 19, 2017, may be exercised • at the latest within seven years from the date of grant. by the beneficiary on the basis of the following vesting schedule: • up to 1/4 on the date of the grant; GENSIGHT BIOLOGICS – 2017 Registration Document– 205